|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 March 2004, Vol. 103, No. 6, pp. 2205-2213. Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-08-2928.
IMMUNOBIOLOGY
Migration of V
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Abstract |
|---|
 Top Abstract IntroductionPatients, materials, and methodsResultsDiscussionReferences |
|---|
1 T cells (2.2%-9.0% of T lymphocytes; healthy donors, 1.0%-2%) and, in some instances, V2 T cells (3.5%-4.8% vs 2.0%-3.3%). In these patients, both V1 and V2 T cells are CXCR3+CXCR4+, whereas in healthy donors CXCR4 was preferentially expressed on V1 T lymphocytes. 
T cells transmigrated across endothelial monolayers, in response to interferon-–inducing protein-10 (IP-10/CXCL10), stromal cell–derived factor-1 (SDF-1/CXCL12), or both, according to the expression of the specific receptors CXCR3 and CXCR4. Interestingly, 6Ckine/SLC/CCL21 was more effective than IP-10/CXCL10 on V1 CXCR3+ cells, whereas V2 CXCR3+ cells were driven more efficiently by IP-10/CXCL10. IP-10/CXCL10– and SDF-1/CXCL12–induced transmigration was dependent on phosphoinositide-3 kinase (PI-3K), as demonstrated by the use of the specific blockers wortmannin and LY294002 and by the activation of the downstream serine kinase Akt/PKB on ligation of CXCR3 and CXCR4. Occupancy of CXCR3, but not of CXCR4, led to CAMKII activation; accordingly, the CAMKII inhibitors KN62 and KN93 decreased IP-10/CXCL10– but not SDF-1/CXCL12–driven transmigration. Finally, HIV-1 Tat, which is present in the serum of HIV-1–infected patients, interferes with the chemotactic activity of these chemokines because of the cysteine-rich domain of the protein, which contains CXC and CC chemokine–like sequences. |
Introduction |
|---|
|
TopAbstractIntroductionPatients, materials, and methodsResultsDiscussionReferences |
|---|
T lymphocytes represent a relevant proportion of the mucosa-associated lymphoid tissue known to be deeply involved in the first-line defense against several pathogens and tumors.1-3 Among T cells, the V2 subset represents most circulating lymphocytes, whereas V1 T cells are resident within epithelial tissues, and it is still unclear whether and how they recirculate.1-3 In AIDS patients, V1 T lymphocytes are increased in the bloodstream and decreased in duodenal mucosa,4,5 suggesting that this subpopulation can recirculate under certain pathologic conditions.
On the other hand, in the acute phase of multiple sclerosis, we reported that the V2 T-cell subset is expanded in the blood of patients. These cells display a high transendothelial migratory capability, apparently in the absence of chemotactic stimuli, and use natural killer receptor protein 1a (NKRP1a/CD161) for this function, through the activation of calcium-calmodulin kinase II (CAMKII).6,7 In contrast, V1 T lymphocytes do not bear NKRP1a and selectively express the platelet-endothelial cell adhesion molecule-1 (PECAM-1), which is involved in their transendothelial migration, leading to the engagement of phosphoinositide-3 kinase (PI-3K) and the activation of Akt/PKB.6,7
Migration of lymphocytes, including T cells, depends not only on the combined actions of various adhesion molecules,8,9 it is controlled by the interactions between chemokines and their receptors.10-14 In human CXC chemokines, 2 of 4 conserved cysteines are separated by an amino acid X, whereas CC chemokines display 2 cysteines side by side.12,13 On the basis of their physiologic features, one can distinguish between "inflammatory" (or inducible) chemokines, which include I-309 (CCL1) and interferon-inducible protein 10 (IP-10, CXCL10), and "homeostatic" (or constitutive) chemokines, such as stromal cell-derived factor-1 (SDF-1, CXCL12) and 6Ckine/SLC (CCL21).13,15,16 Functional studies indicate that circulating T cells migrate in response to chemokine regulated upon activation normal T-cell expressed and secreted (RANTES), macrophage inflammatory protein 1
(MIP-1), MIP-1
, and IP-10.8,14 In terms of chemokine receptors, V2 T lymphocytes express CCR5 (receptor for RANTES, MIP-1, MIP-1) and CXCR3 (whose ligands are represented by IP-10/CXCL10 and 6Ckine/SLC/CCL21),13,15,16 which is not always found on the V1 T-cell surface.14
In the present work, we show that (1) in HIV-1–infected patients, a population of V1 T cells coexpressing CXCR4 and CXCR3 is increased in peripheral blood; (2) V1 and V2 T-cell subsets transmigrate in response to the homeostatic or inflammatory chemokines, IP-10/CXCL10 and SDF-1/CXCL12, according to the expression of their specific receptors CXCR3 or CXCR4; (3) IP-10/CXCL10– and 6Ckine/CCL21-induced transmigration are dependent on PI-3K and CAMKII, activated on the ligation of CXCR3, whereas SDF-1/CXCL12 is dependent only on PI-3K; (4) HIV-1 Tat, present in the serum of HIV-1–infected patients, interferes with the chemotactic activity of IP-10/CXCL10, I-309/CCL1, and SDF-1/CXCL12 because of the cysteine-rich domain of the protein, which contains CXC and CC chemokine–like sequences.16-18
|
Patients, materials, and methods |
|---|
|
TopAbstractIntroductionPatients, materials, and methodsResultsDiscussionReferences |
|---|
Twenty-eight HIV-1–infected patients provided informed consent and were consecutively enrolled in this study conducted at the Infectious Diseases Department (Department of Internal Medicine, University of Genoa). The stage of disease was defined according to the Centers for Disease Control and Prevention (CDC) criteria. Eight patients underwent naive antiretroviral treatment (clinical features, including CD4 and CD8 counts of all patients, are summarized in Table 1). Fifteen seronegative healthy subjects, matched for sex and age, were also studied. HIV-1 RNA was quantitated using the commercial branched DNA (bDNA ultrasensitive assay; Chiron, Amsterdam, Netherlands) with a lower limit of detection of 50 RNA copies mL–1.
|
Monoclonal antibodies and reagents
The anti-V1 monoclonal antibody (mAb) A13 and the anti-V2 mAb BB3 (both immunoglobulin G1 [IgG1]) were prepared as described.19 Phycoerythrin (PE)–conjugated anti-CXCR3 (IgG1) or anti-CXCR4 (IgG2a) mAbs were from BD PharMingen Europe (Milan, Italy). The anti- TCR BMA031 and the anti-V1 mAb MCA2080 were obtained from Serotec (Cergy Saint-Christophe, France). Recombinant interleukin-2 (IL-2) was from Pepro Tec EC (London, United Kingdom); SDF-1, I-309, and IP-10 were from R&D Systems Europe (Oxon, United Kingdom); and 6Ckine was from Biosource International (Camarillo, CA). Cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and with glutamine and penicillin-streptomycin (Biochrom, Berlin, Germany). Phytohemagglutinin (PHA), the PI-3K inhibitors wortmannin and LY294002, goat antimouse (GAM) and murine immunoglobulin were from Sigma Chemical (St Louis, MO), and the CAMKII inhibitors KN62 or KN93 or the inactive compound KN92 were from Calbiochem-Merck (KgaA, Darmstadt, Germany). Anti-Tat rabbit antiserum, synthetic Tat, and the overlapping Tat-derived peptides Tat20-39, Tat24-51, Tat46-60, Tat56-70, and Tat65-80 were purchased from Tecnogen (Piana di Monteverna, Italy); the mutated Tat24-51(25-27Ala) or Tat24-51(30-31Ala) were from PRIMM (Milan, Italy). Biotinylated rabbit anti-Tat IgG was from DBA (Milan, Italy).
Isolation and culture of T-cell populations
Peripheral blood mononuclear cells (PBMCs) from HIV-1–infected patients and healthy donors were isolated using Ficoll-Hypaque gradient. Highly purified CD3+ + T cells were obtained from PBMCs by negative immunodepletion with anti-CD14–, anti-CD4–, and anti-CD8–coated magnetic microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). To obtain V1 or V2 T-cell lines, CD4–CD8– cells were seeded under limiting-dilution conditions in 96-well, U-bottomed microplates (Greiner Laborteckinc, Nurtingen, Germany) and were cultured in RPMI 1640 medium supplemented with 200 mM L-glutamine, 10% FCS, 1 µg/mL PHA, 25 U/mL rIL-2, and 105 irradiated feeder cells (3000 rad [3 Gy]) as described.6 V1 cell lines were A13+MCA2080+, V2 cell lines were BB3+, and all were BMA031-negative (not shown).
Immunofluorescence and cytofluorometric analysis
Direct immunofluorescence on peripheral whole blood of healthy donors and HIV-1–infected patients was performed with the PE-conjugated anti-CXCR3 or CXCR4 mAbs and the anti-TCRV1 MCA2080 or the A13 or BB3 mAbs labeled with the Zenon Alexafluor 488 mouse IgG1 Labeling Kit (Molecular Probes Europe BV, Leiden, Netherlands). Immunofluorescence staining of cultured cells was performed as described elsewhere.6 Control aliquots were stained with fluorochrome-conjugated, isotype-matched, irrelevant mAbs. Samples were analyzed on a flow cytometer (FACSort; Becton Dickinson) equipped with an argon ion laser exciting Alexafluor 488 and PE at 488 nm. Data were analyzed using Lysis II (version 1.1; Becton Dickinson) and are expressed as Log red fluorescence intensity (arbitrary units [au]) versus Log green fluorescence intensity (au) or compared with number of cells. Calibration was assessed with Calibrite particles using the AutoCOMP computer program (Becton Dickinson).
Transendothelial migration assay
Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as described6,7 and were used within 4 passages. Endothelial confluent monolayers were tested for their integrity before the migration assay, as described, using Transwell cell culture chambers (polycarbonate filters, 3-µ pore size; Costar, Cambridge, MA).6,7 V1 or V2 T cells were recovered, washed twice, and exposed to 50 ng/mL IP-10/CXCL10, I-309/CCL1, SDF-1/CXCL12, or C6Kine/SCL/CCL21 added to the lower chamber during transmigration. In some experiments, V1 or V2 T-cell lines were preincubated for 10 minutes at 4°C with 100 nM Tat or Tat peptides or for 30 minutes with wortmannin (1-100 nM) or LY294002 (0.2-20 µM), KN62 or KN93 or KN92 (0.1-10 µM) and were washed before the transmigration assay. In other experiments, cells from HIV-1–infected patients were incubated with autologous serum (1:2 dilution), in the absence or presence of the rabbit anti-Tat antiserum (Tecnogen) used at 1:400 dilution. To quantitatively express the results of transmigration assays, V1 or V2 T-cell lines were labeled with chromium Cr 51 (51Cr; sodium chromate; NEN, Boston, MA) and were added to the upper compartment of the Transwell chamber, as described.6,7 At different time points, migrated cells were recovered from the lower compartment of the chamber and were lysed with 100 mM Tris-HCl (pH 7.4) 0.1% Triton X-100. The radioactivity of the samples was measured in a gamma-counter. Results are expressed as the percentage of migrating cells calculated as described.6,7 Statistical analysis was performed using the Student t test.
Measurement of CAMKII or PI-3K activation
CAMKII activation in cells was tested on cross-linking of CXCR3, CXCR4, T-cell receptor (TCR) obtained with the specific mAbs (5 µg/mL) followed by GAM, in the absence or presence of the CAMKII inhibitor KN62 or with the inactive compound KN92. CAMKII was measured with the CAMKII assay kit, using the specific substrate and 32P- adenosine triphosphate (ATP), after immunoprecipitation with the specific anti-CAMKII antibody (Upstate Biotechnology, Lake Placid, NY) and chromatography.7 Results are expressed as cpm x 10–3 and are the mean ± SD of triplicate samples. PI-3K activity was tested indirectly by analyzing the phosphorylation of the downstream serine/threonine kinase Akt1/PKB (p-Akt) in cell lysates of T cells, assessed with the enzyme-linked immunosorbent assay (ELISA) kit (BioSource Europe, Nivelles, Belgium) on the ligation of CXCR3 or CXCR4, in the presence or absence of the PI-3K inhibitor LY294002. As a control, cells were exposed to murine immunoglobulin plus GAM. The same samples were analyzed for the content of total Akt with a specific ELISA assay kit (BioSource). Results are expressed as the percentage of p-Akt, normalized for total Akt (units/106 cells), and are the mean ± SD of 3 independent experiments.
Measurement of Tat in patient sera
Tat was measured in the serum of HIV-1 patients by ELISA using a rabbit anti-Tat antiserum (10 µg/mL), directed to synthetic Tat, as capture antibody and a biotinylated rabbit anti-Tat antiserum (1 µg/mL), raised against recombinant Tat, as detection antibody, followed by avidin–horseradish peroxidase (Av-HRP, 1:2000; Sigma) and by the substrate (2,2'-azino-bis(3-ethylbenzthyazoline-6-sulfonic acid); Sigma). Sera from HIV-1–HBV+/HCV+ patients or healthy donors were analyzed for comparison. Optical density (OD) of each sample was measured at 450 nm, and results expressed in nanograms per milliliter were referred to synthetic Tat used as the standard.
|
Results |
|---|
|
TopAbstractIntroductionPatients, materials, and methodsResultsDiscussionReferences |
|---|
1 or V2 T-cell subsets in HIV-1–infected patients and healthy donors
Cytofluorometric analysis of peripheral whole blood of 28 HIV-1–infected patients showed that 19 of 28 patients have increased levels of circulating V1 T cells that usually belong to the "resident" T-cell population, ranging between 2.2% and 9.0% of T lymphocytes (healthy donors, 0.4%-2.3%; Figure 1A; Table 2). Five of these patients also displayed an increased percentage of V2 T cells (3.2%-4.8% vs 0.8%-3.1% in healthy donors; Figure 1B; Table 2).
|
|
To understand the mechanisms possibly underlying the increased number of circulating V1 T cells in HIV-1–infected patients, we analyzed the expression of CXCR3 and CXCR4 chemokine receptors on V1 and V2 T cells, in the peripheral blood of healthy donors or HIV-1–infected patients. We found that in 11 of 15 healthy donors, V1 T lymphocytes are CXCR4+ (Figure 2A; Table 2), with 70% of the cells CXCR3+ and 30% CXCR3– (Figure 2B; Table 2). In 4 donors, however, V1 T cells were CXCR4dull or negative (Figure 2C; Table 2). The V2 T-cell subset was CXCR4dull (Figure 2D) or negative in most of the donors (Figure 2F; Table 2); furthermore, V2 T cells were always CXCR3+ (Figure 2E; Table 2).
|
In HIV-1–infected patients, both V1 and V2 T cells were CXCR3+ (Figure 3, panels A and E for V1, panels C and G for V2 subset) and CXCR4+ (panel B for V1, panel D for V2 cells). In some (4 of 28) cases either population was CXCR4dull or negative (Figure 3F, H). Thus, the main difference between healthy donors and HIV-1–infected patients, in addition to the number of circulating V1 T cells, is the expression of CXCR4 on V1 and V2 populations in HIV-1 patients.
|
Migratory response to homeostatic or inflammatory chemokines by V1 or V2 T lymphocytes
We further investigated the ability of the 2 T-cell subsets to transmigrate across endothelial monolayers in response to CXCR3 or CXCR4 chemokines. To this aim, T-cell lines were derived from healthy donors; clones preferentially expressing CXCR3 or CXCR4 or coexpressing the 2 chemokine receptors, obtained from healthy donors, were selected for further functional studies. Fluorescence-activated cell sorter (FACS) analysis of cloned V2 or V1 T lymphocytes obtained from healthy donors showed that both subpopulations are CCR5+ CCR3–, in keeping with previous data,14 and display different phenotypes with regard to CXCR3 or CXCR4 expression or coexpression. Among 40 V2 and 30 V1 clones analyzed, obtained from 6 healthy donors, 24 V2 clones were CXCR3+ CXCR4–, 3 were double negative, 8 were double positive, and 5 were CXCR3– and CXCR4+; on the other hand, 12 V1 clones were CXCR3– and CXCR4+, 4 were double negative, 4 were double positive, and 10 were CXCR3+ CXCR4– (not shown in figures or tables).
Bulk cultured V2 T cells that were CXCR3bright and CXCR4dull displayed more efficient, faster kinetics of transendothelial migration to IP-10/CXCL10, which binds to CXCR3 (Figure 4A; mean ± SD of 6 cell lines from 6 healthy donors), than to the CXCR4-specific chemokine SDF-1; in turn, SDF-1 was more effective for V1 T cells, expressing CXCR3dull and CXCR4bright (Figure 3B; mean ± SD of 6 cell lines from 6 healthy donors). Both subsets responded to I-309/CCL1 (Figure 3A-B). A certain degree of spontaneous (nonchemokine-driven, Nil in Figure 4) transendothelial migration was observed at 40 minutes, particularly for V2 T lymphocytes, in agreement with our previous reports.6,7
|
Along this line, CXCR3+ V2 clones (clone LP50.1 and LP50.11 in Figure 5A, C) migrated when challenged with IP-10/CXCL10, whereas BC100.8, which did not respond to this chemokine (Figure 5B), was CXCR3 negative. On the other hand, the CXCR4+ V1 clones (A25.5 and A25.3) migrated in response to SDF-1/CXCL12 (Figure 5E-F), whereas the V1 clone BC50.2, which did not respond to this chemokine (Figure 5D), was CXCR4 negative. Given that V1 T-cell clones expressing CXCR3 (clone BC50.2 and A25.3) were less responsive to IP-10 than CXCR3+ V2 clones (LP50.1 and LP50.11), we used 6CK/SLC/CCL21, a tissue-related, homeostatic chemokine known to interact with CXCR3,13,15,16 in transendothelial migration assays. Interestingly, 6Ckine/SLC/CCL21 was more effective than IP-10/CXCL10 in inducing the transmigration of V1/CXCR3+ clones (Figure 5D, F), at variance with V2/CXCR3+ cells, which were driven more efficiently by IP-10/CXCL10 (Figure 5A, C). Similarly, when V2 T-cell clones expressed CXCR4 (BC100.8 and LP50.11), they showed a slower kinetics of response to SDF-1/CXCL12 (Figure 5B-C) than V1/CXCR4+ clones (Figure 5E-F).
|
Superimposable results were obtained with 14 clones (not shown), derived from 6 donors and expressing the different phenotypes cited in Figure 5. Taken together these data suggest that, in healthy persons, the resident V1 T-cell population preferentially responds to homeostatic, constitutive chemokines, whereas circulating V2 T cells are more sensitive to inflammatory chemokines.
Role of PI-3K and CAMKII in SDF-1 or IP-10/6CKine-driven transmigration of T-cell subsets
It has been reported that CXC chemokines can stimulate PI-3K–dependent chemotaxis of leukocytes20; in particular, this enzyme is involved in the SDF-1–induced polarization of lymphocytes21 and sustains prolonged signal transduction through either CXCR4 and CXCR3.23,24 In addition, we reported that the transendothelial migration of V2 lymphocytes requires the activation of CAMKII.7
To determine the role of these kinases in the chemokine-driven migration of V1 or V2 T lymphocytes, these 2 cell subsets were exposed to either PI-3K or CAMKII inhibitors and then were added to endothelial monolayers. These experiments were performed at 60 minutes because at this time point the difference between basal and chemokine-driven migration of both T-cell subsets was maximal (Figure 4). We found that transendothelial migration of V2 or V1 T lymphocytes induced by IP-10 or SDF-1, respectively, was inhibited by the PI-3K blockers LY294002 (Figure 6A) or wortmannin (Figure 6B), in agreement with the finding that CXCR3 and CXCR4 receptors are coupled to this kinase.22,23 Of note, when V2 or V1 T lymphocytes were challenged by IP-10/CXCL10 (Figure 6C) or by 6CK/SLC/CCL21 (not shown), respectively, both acting on CXCR3, transendothelial migration of the 2 T-cell subsets was inhibited by the CAMKII-specific inhibitor KN62. By contrast, KN62 was not effective on cell migration induced by SDF-1/CXCL12 on the V1 subpopulation expressing the specific CXCR4 receptor (Figure 6D). Similar results were obtained with another CAMKII blocker, KN93 (not shown), but not with the inactive compound KN92 (Figure 6C-D). Thus, at variance with CXCR4, CXCR3 appears to be coupled to PI-3K and CAMKII signal transduction pathways.
|
To further confirm these data, CAMKII activity and PI-3K–dependent activation of the downstream serine-kinase Akt/PKB were measured in T cells with the ligation of CXCR3 or CXCR4, in comparison with V1 or V2 TCR, by the use of the specific mAbs. As shown in Figure 6E, triggering CXCR3 on a CXCR3+ V2 T-cell clone (BC25.10) led to the activation of Akt/PKB, which was inhibited by the PI-3K blocker LY294002; of note, CXCR3 oligomerization also elicited CAMKII activation, which was reduced in the presence of the specific blocker KN62 (Figure 6F). In turn, CXCR4 engagement on the CXCR4+ V1 T-cell clone A25.5 could only induce the triggering of Akt/PKB (Figure 6E), but not that of CAMKII (Figure 6F). These data indicate that CXCR3-driven transendothelial migration and signal transduction are dependent on CAMKII in addition to PI-3K.
Although not shown, it should be mentioned that either CAMKII or PI-3K blockers could inhibit spontaneous (in the absence of chemokines) transendothelial migration of V2 (from 15% ± 5% to 5% ± 3% when exposed to KN62) or V1 (from 10% ± 3% to 4% ± 2% in the presence of LY294002 or wortmannin) T cells, respectively. This is because, in the absence of chemokines, during transendothelial migration CAMKII is activated by NKRP1a on V2 T cells, whereas PI-3K is engaged by PECAM-1 on V1 T lymphocytes.7
Interference by HIV-1 Tat amino acid sequence containing CC or CXC motifs on chemokine-driven transmigration of T cells
HIV-1 Tat has been reported to function as an antagonist for CXCR4.24 Indeed, HIV-1 Tat contains a CXC chemokine–like sequence (amino acids [aa's] 25-27), in addition to a CC-like sequence (aa's 30-31) residing inside the cysteine-rich domain of the protein.17,24 Furthermore, we reported that exogenous Tat interferes with CAMKII and, to a lesser extent, with PI-3K in dendritic cells and natural killer cells.25,26 Thus, we investigated whether HIV-1 Tat could interfere with the CXC or CC chemokines active on V1 or V2 T lymphocytes by the use of synthetic overlapping peptides.
It is of note that the synthetic peptides Tat24-51 and Tat20-39, both containing the CXC (aa's 25-27) or CC-like (aa's 30, 31) sequences, could exert a dose-dependent inhibition of transendothelial migration induced on V2 T lymphocytes by IP10/CXCL10 and on V1 T cells by SDF-1/CXCL12 (Table 3). As expected, the RGD containing Tat65-80, but not the mutated Tat65-80RGE, peptide also displayed inhibitory activity (Table 3), conceivably because of the block of integrin-mediated cell-matrix adhesion.24 At variance, the basic domain Tat46-60 and the Tat56-70 encompassing the sequence between the basic and the RGD region were not effective (Table 3). The finding that Tat20-39 at low concentrations was less effective than the partially overlapping Tat24-51 in decreasing the migration of the 2 cell subsets might be attributed to the last 4 amino acids (GRKK) of the former peptide, resembling aa's 1987-1990 of fibronectin,27 which is conceivably present in the extracellular matrix of cultured HUVECs. Thus, Tat can downregulate CXCR3- and CXCR4-mediated functions.
|
The inhibitory activity of the 2 cysteine-containing, Tat-derived synthetic peptides (Tat24-51 and Tat20-39) on chemokine-driven transmigration of T cells was caused by the CXC- or CC-like sequences of these peptides, as demonstrated by experiments of transendothelial migration performed in the presence of Tat24-51 mutated in the CXC (Tat25-27Ala peptide) or in the CC (Tat 30-31Ala peptide) sequence. Figure 7 shows that transmigration induced by IP-10/CXCL10 on V2 (Figure 7A, white columns) or by SDF-1/CXCL12 on V1 T lymphocytes (Figure 7B, white columns) was strongly inhibited by wild-type Tat 24-51 and by the same peptide that conserves the CXC sequence but is mutated in the CC region (Tat30-31Ala); conversely, no inhibition of the migration induced by the 2 CXC-chemokines was observed when Tat24-51 peptide mutated in the CXC sequence (Tat25-27Ala) was used (Figure 7A-B). Along this line, Tat24-51 mutated in the CC sequence (Tat30-31Ala) did not interfere with the CC chemokine I-309 (Figure 7A for V2 and Figure 7B for V1 T cells, gray columns); on the other hand, Tat24-51 wild-type and Tat25-27Ala, maintaining the CC sequence, were effective in the inhibition of I-309–driven cell migration (Figure 7A-B, gray columns).
|
In keeping with these results, synthetic Tat was able to inhibit transendothelial migration in response to IP-10 or to SDF-1 of V2 or V1 T-cell lines (Figure 7C-D, respectively) obtained from 2 patients (patient 18 and patient 21; superimposable results were obtained with T-cell lines from other 4 patients; not shown). Of note, the autologous serum of these patients could inhibit T-cell migration, and this inhibition was neutralized using a rabbit anti-Tat antiserum (Figure 7C-D), indicating that Tat is present in patient sera, as previously described.28 Indeed, we detected HIV-1 Tat (150-550 ng/mL) in the serum of 24 of 28 HIV-1–infected patients (Table 4), suggesting that the effects of this viral product can conceivably be found in vivo.
|
|
Discussion |
|---|
|
TopAbstractIntroductionPatients, materials, and methodsResultsDiscussionReferences |
|---|
1 T cells are increased in the peripheral blood of HIV-1–infected patients and express CXCR3, CXCR4, or both; (2) transendothelial migration driven by CXC and CC chemokines are inhibited by HIV-1 Tat in the serum of HIV-1–infected patients; (3) transmigration of these cells, obtained from healthy donors, in response to CXCR3-specific chemokines is dependent on CAMKII in addition to PI-3K.
According to their expression of CXCR3 or CXCR4, V1 and V2 T-cell lines and clones from healthy donors transmigrate across endothelial monolayers in response to the specific chemokines, IP-10/CXCL10 for CXCR3+ cells and SDF-1/CXCL12 for CXCR4+ clones. The finding that the homeostatic chemokine 6Ckine/SLC/CCL21 was more effective than IP-10/CXCL10 in driving transendothelial migration of the V1 clones expressing CXCR3 suggests that the resident V1 T-cell population preferentially responds to homeostatic, constitutive chemokines. In this regard, V1 T cells also bear CCR7 (not shown), which is reported to be expressed on bovine T lymphocytes and drives tissue localization of these cells in response to 6Ckine/SLC/CCL21.29 On the other hand, V2 CXCR3+ cells were driven more efficiently by IP-10/CXCL10, supporting that circulating V2 T cells are more sensitive to inflammatory chemokines. However, it is conceivable that the redistribution of V1 and V2 cell subsets during inflammation is regulated by cytokines, such as tumor necrosis factor- (TNF-), which increase adhesiveness to vascular endothelium, thus influencing migratory capabilities of lymphocytes. Indeed, when transmigration was performed on endothelial monolayers exposed to TNF-, the difference in the response of the 2 T-cell subsets to homeostatic and inflammatory chemokines was less evident (not shown).
In addition, we show that CXCR3 can activate CAMKII, which is needed for transendothelial migration mediated by IP-10/CXCL10; conversely, CAMKII is not involved in SDF-1/SLC/CXCL12-driven transmigration. We also found that transmigration of the 2 T-cell subsets induced by IP-10/CXCL10, 6Ckine/SLC/CCL21, or SDF-1/CXCL12 was dependent on PI-3K activation, in agreement with the reported finding that CXCR3 and CXCR4 receptors are coupled to this kinase.20-23
Each of these kinases has been implied in the regulation of cell locomotion—CAMKII controlling calcium-dependent microtubule assembly,30 and PI-3K triggering haptotactic movements driven by extracellular matrix components.31 In agreement with these data, we have reported that CAMKII is engaged by NKRP1a in the V2 T-cell subset during transmigration, whereas the activation of PI-3K through PECAM-1 drives transendothelial migration of V1 T cells.7 Moreover, the chemokine-induced high-affinity state of 2 integrins is controlled by PI-3K–dependent signal transduction, possibly influencing the first steps of tethering and rolling to endothelium.32 Thus, the preferential use of a PI-3K– or a CAMKII-dependent pathway by each subset of T lymphocytes may indicate that they can be recruited by distinct chemokines produced during immune reactions. Indeed, it has been proposed that chemokines selectively expressed by vascular or lymphatic endothelial cells are involved in the regulation of leukocyte extravasation, blood-to-lymph migration, and trafficking to the lymph nodes.33,34 Likewise, chemokine production by intraepithelial T cells and the preferential response of or T cells to defined chemokines may play a key role in the regulation of inflammation and tissue injury or damage.35-37
Of note, V1 and V2 T-cell lines from HIV-1–infected patients coexpress CXCR3 and CXCR4. In healthy donors, who have a lower count of peripheral V1 T cells, CXCR4 was mostly expressed on this subset. According to the receptor expressed, T cells from HIV-1–infected patients migrated in response to the specific chemokines. It is of interest that CXCR3 and CXCR4 are reported markers of T cells associated with certain acute inflammatory and viral diseases, including HIV-1 infection.38,39 Thus, it is conceivable that in the patients analyzed, the up-regulation of CXCR3 and CXCR4 on T cells is a consequence of HIV-1 infection. In addition, it has been proposed that subversion of the immune system through the release of products exerting chemokine mimicry might occur during viral diseases, including the early stages of HIV-1 infection.11,40,41 In particular, specific herpesviruses and lentiviruses can produce chemokine mimics able to block chemokine action and facilitate viral dissemination.41
Our finding that the cysteine-rich domain of HIV-1 Tat protein, which contains chemokine-like sequences, can interfere with the effects of CXC and CC chemokines on T cells is of interest. Indeed, the early production of Tat, which is present in the serum and which inhibits the chemokine-driven transmigration of T cells in these patients, may counteract the effects of chemokines released in response to viral infection, such as I-309/CCL1, and may impair the recruitment of cells with antiviral properties. This mechanism may account, at least in part, for the reported redistribution of the 2 T-cell subsets: the resident one increases in peripheral blood in early AIDS and it decreases from intestine in advanced disease,5,42,43 supporting the importance of T cells as part of the initial defense against HIV-1 infection.5,44-46 In agreement with this, we found that patients with a high percentage of circulating V1 T cells also have considerable amounts of Tat in the serum (200-500 ng/mL); conversely, patients with low or undetectable levels of Tat (50-150 ng/mL) display a number of V1 T lymphocytes in peripheral blood equivalent to that of healthy donors. We are aware that we cannot draw any definitive conclusion from these data because in a few patients, serum Tat levels and V1 T-cell numbers were discordant. Nevertheless, as mentioned, other viral factors may influence the distribution of T-cell subsets in peripheral blood and in mucosal tissues; indeed, the inhibition of chemotaxis in response to SDF-1/CXCL12 has also been reported for at least another HIV-1 product, Nef.44 It is tempting to speculate that evaluating the V1/V2 ratio in peripheral blood might contribute, in the future, to the follow-up of the disease. Finally, studying the viral mimicry of chemokines and chemokine receptors may provide new concepts in the understanding of viral immunopathogenesis and may help in the development of new anti-inflammatory or antiviral drugs and vaccines.
|
Footnotes |
|---|
Prepublished online as Blood First Edition Paper, November 20, 2003; DOI 10.1182/blood-2003-08-2928.
Supported in part by the Italian Ministero della Salute (A.P., M.R.Z. Coordinated Grant Special Project), the Italian Istituto Superiore di Sanità (IV National Project on AIDS Research), and the Italian Association for Cancer Research (A.P., M.R.Z).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alessandro Poggi, Laboratory of Immunology, National Institute for Cancer Research, Largo R. Benzi 10, I-16132, Genoa, Italy; e-mail: poggi{at}vega.cba.unige.it.
|
References |
|---|
|
TopAbstractIntroductionPatients, materials, and methodsResultsDiscussionReferences |
|---|
T lymphocytes. Immunol Today.1989;10: 186-188.[CrossRef][Medline]
[Order article via Infotrieve] T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18: 975-1026.[CrossRef][Medline]
[Order article via Infotrieve] T lymphocytes: a nonredundant system in the immune surveillance against cancer. Trends Immunol. 2002;23: 14-18.[CrossRef][Medline]
[Order article via Infotrieve]1 T cells expanded in the blood throughout HIV infection display cytotoxic activity and are primed for TNF- and IFN- production, but are not selected in lymph nodes. J Immunol 1997;159: 3629-3637.[Abstract]2+TCR+ T lymphocytes from healthy donors and multiple sclerosis patients. J Immunol. 1999; 162: 4349-4354.1+TCR+ and V2+TCR+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. J Immunol. 2002;168: 6071-6077. T lymphocytes: strong expression of CCR5 is a selective feature of V2/V9 T cells. J Immunol. 2002;168: 4920-4929.–induced lymphocyte polarization and chemotaxis. J Immunol. 1999;163: 4001-4012.3-mediated engulfment of apoptotic tumor cells by dendritic cells is dependent on CAMKII: inhibition by HIV-1 Tat. J Leukoc Biol. 2002;71: 531-537.64-associated erb-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on 31 integrin. J Cell Biol. 2001;153. 465-478.2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity. 2000; 13: 759-769.[CrossRef][Medline]
[Order article via Infotrieve]1 integrin I-domain. Eur J Immunol. 1998;28: 2530-2536.[CrossRef][Medline]
[Order article via Infotrieve]+ T cells in the peripheral blood and bone marrow as a selective feature of HIV-1 but not other virus infections. Br J Haematol. 1998;100: 728-734.[CrossRef][Medline]
[Order article via Infotrieve] T cells in generating antiviral factors and -chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol. 2000;30: 2245-2256.[CrossRef][Medline]
[Order article via Infotrieve]9V2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis. 2002;186: 847-850.[CrossRef][Medline]
[Order article via Infotrieve]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Fenoglio, A. Poggi, S. Catellani, F. Battaglia, A. Ferrera, M. Setti, G. Murdaca, and M. R. Zocchi V{delta}1 T lymphocytes producing IFN-{gamma} and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans Blood, June 25, 2009; 113(26): 6611 - 6618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Faller, J. Kakal, R. Kumar, and P. MacPherson IL-7 and the HIV Tat protein act synergistically to down-regulate CD127 expression on CD8 T cells Int. Immunol., March 1, 2009; 21(3): 203 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kosub, G. Lehrman, J. M. Milush, D. Zhou, E. Chacko, A. Leone, S. Gordon, G. Silvestri, J. G. Else, P. Keiser, et al. Gamma/Delta T-Cell Functional Responses Differ after Pathogenic Human Immunodeficiency Virus and Nonpathogenic Simian Immunodeficiency Virus Infections J. Virol., February 1, 2008; 82(3): 1155 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kittiworakarn, A. Lecoq, G. Moine, R. Thai, E. Lajeunesse, P. Drevet, C. Vidaud, A. Menez, and M. Leonetti HIV-1 Tat Raises an Adjuvant-free Humoral Immune Response Controlled by Its Core Region and Its Ability to Form Cysteine-mediated Oligomers J. Biol. Chem., February 10, 2006; 281(6): 3105 - 3115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Zocchi, P. Contini, M. Alfano, and A. Poggi Pertussis Toxin (PTX) B Subunit and the Nontoxic PTX Mutant PT9K/129G Inhibit Tat-Induced TGF-{beta} Production by NK Cells and TGF-{beta}-Mediated NK Cell Apoptosis J. Immunol., May 15, 2005; 174(10): 6054 - 6061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Deng, T. A. Moore, M. W. Newstead, X. Zeng, A. M. Krieg, and T. J. Standiford CpG Oligodeoxynucleotides Stimulate Protective Innate Immunity against Pulmonary Klebsiella Infection J. Immunol., October 15, 2004; 173(8): 5148 - 5155. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
1 and V
) or presence of the chemokines SDF-1/CXCL12 (
), IP-10/CXCL10 (
), I-309/CCL1 (
), all at 50 ng/mL. Results are expressed as percentage of transendothelial migration, calculated as described in "Patients, materials, and methods," and are the mean ± SD from 6 independent experiments with cell lines from 6 donors. *Student t test; P < .05.
indicates V
). Results are expressed as percentage units of pAkt compared with total Akt/106 cells (mean ± SD of 3 independent experiments). (F) CAMKII activity assessed using the specific substrates and 32P-
) or SDF-1/CXCL12 (B, 
) were assayed for transmigration across HUVEC monolayers at 60 minutes, in the presence of 50 ng/mL IP-10/CXCL10 (C) or SDF-1/CXCL12 (D), as described in "Patients, materials, and methods." In some experiments, cells were preincubated with 0.1 µg/mL Tat or with autologous serum (1:2 dilution) alone or with an anti-Tat antiserum (1:400 dilution), as indicated. Nil indicates migration in the presence of the indicated chemokine, without Tat. Results are expressed as percentage of cell migration, calculated as described in "Patients, materials, and methods," and are the mean ± SD from 3 independent experiments. *Student t test; P < .05.